Abstract 1579P
Background
Worldwide, AYA care for patients < 25 years is mostly delivered by paediatric oncologists. For the whole range of patients at AYA age (15- 39 years) there is a need for AYA care in adult oncology practices. In 2014, a national AYA network with central coordination, started in the Netherlands (NL) in 7 university medical centres and a cancer centre, with the aim to extend to a nationwide network in the adult oncology environment. This network, co-designed by healthcare professionals (HCPs), patients and caregivers, has evolved towards a data driven learning healthcare system and may be a model for other countries as well.
Methods
From its start, with very limited resources, annual plans were made with lean deliverables, topics on AYA care domains were addressed, (mandatory) teaching modules for HCPs have been developed, and AYA research projects were written with the aim to constantly feed data into the educational and care initiatives of the network.
Results
In ten years, the number of hospitals delivering AYA care has expanded to 75; since 2024 AYA care and network-management is reimbursed by healthcare insurance companies. Research projects have been awarded from the Dutch Cancer Society, Dutch Scientific Council and EU Horizon program. COMPRAYA – a prospective study to collect clinical, biological and psychosocial data, GENAYA - a collection of whole genome sequencing data, INVAYA and CORDAYA –research projects for AYAs with an uncertain or poor prognosis and SURVAYA investigating AYAs 5-20 years after diagnosis, all generate data to constantly improve AYA care. Our awarded EU project STRONG AYA, with federated data collection running in NL, UK, France, Poland and Italy will generate data for individual countries and will ensure benchmarking to improve AYA care at pan-European level. Results of projects are evaluated regularly by master and PhD students with medical, psychosocial and econometry background and postdoctoral researchers, supervised by the core team. Teaching modules are adapted and developed based on the obtained data.
Conclusions
The model of a learning AYA-healthcare system enables collaborative (inter)national data driven initiatives, which has the advantage to improve AYA care at an (inter)national and local level.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10